These findings highlighted the prodiabetogenic activity of IL-21 on diverse genetic backgrounds, which suggests that the use of IL-21 antibodies, blocking agents, or IL-21R-Fc fusion proteins could be a promising therapeutic target for the prevention or treatment of T1DM [15]. Here, IL21R is linked to type 1 diabetes mellitus.